#JITC Research: Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry https://t.co/PHdUVOksIo https://t.co/Ih69V5jV2B
19,289 followers
19,289 followers
#JITC Research: Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry https://t.co/PHdUVOksIo https://t.co/6HB6VS17go
440 followers
RT @sitcancer: #JITC Research: Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metas…
19,289 followers
#JITC Research: Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry https://t.co/PHdUVOksIo https://t.co/gFN8nf5bey